BioMarin: Rights To Kuvan Data Licensed To Asubio Pharma (Japan)
This article was originally published in PharmAsia News
BioMarin Pharmaceutical Inc. has licensed exclusive rights to data and intellectual property contained in the Kuvan new drug application to Japanese drug firm Asubio Pharma Co. Ltd. Asubio will use the data to supplement its current filing to the Japanese Ministry of Health, Labour and Welfare for approval of its BH4 product for the treatment of phenylketornuria in Japan. (Click here for more - May Require Paid Subscription
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.